These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 38047423)

  • 21. Imeglimin Hydrochloride: First Approval.
    Lamb YN
    Drugs; 2021 Sep; 81(14):1683-1690. PubMed ID: 34472031
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Factors contributing to the clinical effectiveness of imeglimin monotherapy in Japanese patients with type 2 diabetes mellitus.
    Hagi K; Kochi K; Watada H; Kaku K; Ueki K
    J Diabetes Investig; 2024 May; ():. PubMed ID: 38794986
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Imeglimin: Current Development and Future Potential in Type 2 Diabetes.
    Konkwo C; Perry RJ
    Drugs; 2021 Feb; 81(2):185-190. PubMed ID: 33247829
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.
    Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
    Cochrane Database Syst Rev; 2016 Oct; 10(10):CD012151. PubMed ID: 27749986
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-world effectiveness of imeglimin in patients with type 2 diabetes: A retrospective longitudinal study in Japan.
    Katsuyama H; Hakoshima M; Heshiki T; Iida S; Adachi H; Yanai H
    Diabetes Res Clin Pract; 2024 Jul; 213():111752. PubMed ID: 38908549
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.
    Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
    Cochrane Database Syst Rev; 2017 May; 5(5):CD012204. PubMed ID: 28489279
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Absence of QTc prolongation in a thorough QT study with imeglimin, a first in class oral agent for type 2 diabetes mellitus.
    Dubourg J; Perrimond-Dauchy S; Felices M; Bolze S; Voiriot P; Fouqueray P
    Eur J Clin Pharmacol; 2020 Oct; 76(10):1393-1400. PubMed ID: 32556539
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Resveratrol for adults with type 2 diabetes mellitus.
    Jeyaraman MM; Al-Yousif NSH; Singh Mann A; Dolinsky VW; Rabbani R; Zarychanski R; Abou-Setta AM
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011919. PubMed ID: 31978258
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.
    Madsen KS; Chi Y; Metzendorf MI; Richter B; Hemmingsen B
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD008558. PubMed ID: 31794067
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular Mechanisms by Which Imeglimin Improves Glucose Homeostasis.
    Yaribeygi H; Maleki M; Sathyapalan T; Jamialahmadi T; Sahebkar A
    J Diabetes Res; 2020; 2020():8768954. PubMed ID: 32215274
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of teneligliptin in patients with type 2 diabetes mellitus: a Bayesian network meta-analysis.
    Zhu M; Guan R; Ma G
    Front Endocrinol (Lausanne); 2023; 14():1282584. PubMed ID: 38189048
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Imeglimin increases glucose-dependent insulin secretion and improves β-cell function in patients with type 2 diabetes.
    Pacini G; Mari A; Fouqueray P; Bolze S; Roden M
    Diabetes Obes Metab; 2015 Jun; 17(6):541-545. PubMed ID: 25694060
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A review of phenformin, metformin, and imeglimin.
    Yendapally R; Sikazwe D; Kim SS; Ramsinghani S; Fraser-Spears R; Witte AP; La-Viola B
    Drug Dev Res; 2020 Jun; 81(4):390-401. PubMed ID: 31916629
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics of Imeglimin in Caucasian and Japanese Healthy Subjects.
    Fouqueray P; Chevalier C; Bolze S
    Clin Drug Investig; 2022 Sep; 42(9):721-732. PubMed ID: 35867199
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of dipeptidyl peptidase-4 inhibitors and pioglitazone combination therapy versus pioglitazone monotherapy in type 2 diabetes: A system review and meta-analysis.
    Wang B; Sun Y; Sang Y; Liu X; Liang J
    Medicine (Baltimore); 2018 Nov; 97(46):e12633. PubMed ID: 30431561
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The safety and efficacy of once-weekly glucagon-like peptide-1 receptor agonist semaglutide in patients with type 2 diabetes mellitus: a systemic review and meta-analysis.
    Li X; Qie S; Wang X; Zheng Y; Liu Y; Liu G
    Endocrine; 2018 Dec; 62(3):535-545. PubMed ID: 30101378
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Imeglimin: features of the mechanism of action and potential benefits].
    Kuznetsov KO; Saetova AA; Mahmutova EI; Bobrik AG; Bobrik DV; Nagaev IR; Khamitova AD; Arapieva AM
    Probl Endokrinol (Mosk); 2022 Mar; 68(3):57-66. PubMed ID: 35841169
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
    Ipsen EØ; Madsen KS; Chi Y; Pedersen-Bjergaard U; Richter B; Metzendorf MI; Hemmingsen B
    Cochrane Database Syst Rev; 2020 Nov; 11(11):CD013516. PubMed ID: 33210751
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Pharmacological profile and clinical efficacy of imeglimin hydrochloride (TWYMEEG
    Nagamine J
    Nihon Yakurigaku Zasshi; 2023; 158(2):193-202. PubMed ID: 36858505
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.
    Lo C; Toyama T; Wang Y; Lin J; Hirakawa Y; Jun M; Cass A; Hawley CM; Pilmore H; Badve SV; Perkovic V; Zoungas S
    Cochrane Database Syst Rev; 2018 Sep; 9(9):CD011798. PubMed ID: 30246878
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.